Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.
Develops CAR-T cell therapies for blood cancers; co-markets Carvykti for multiple myeloma with Johnson & Johnson.
Janssen, Johnson & Johnson's drug unit, sells Carvykti, and the two companies share costs and profits, so Legend's income arrives as collaboration payments rather than direct drug sales. Each dose is made from the individual patient's own cells, so manufacturing capacity limits how many patients can be treated.
Moat: narrow (IP / patents, process know-how, regulatory licence). Complex CAR-T manufacturing and J&J's global commercial reach are hard to replicate quickly.
Headquarters: Somerset, New Jersey, US · Founded: 2014 · Employees: 2,900
Size Legend Biotech Corp. Sponsored ADR (LEGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.12B, the 1507th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.25 on 18 Nov 2026.
Performance Over six months the shares fell 42.2%, against +1.9% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 49.7% over the last twelve months (peer median +14.8%); the operating margin is 2.8% (peer median 14.8%).
Valuation It trades at 34.2× forward earnings against a peer median of 20.7× (7th most expensive of 17).
Capital Return on invested capital runs 2.6 points below its cost of capital (7.7% WACC).
Short interest Short interest is 6.1% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.36B | $1.03B | $628M | $285M | $117M |
| Revenue growth | — | +64% | +120% | +144% | — |
| Gross profit | $726M | $593M | $369M | $120M | $33.2M |
| EBITDA | $88.4M | -$108M | -$286M | -$421M | -$439M |
| Net income | -$318,707 | -$298M | -$177M | -$518M | -$446M |
| Free cash flow | -$336M | -$168M | -$210M | -$503M | -$235M |
| Capital expenditure | $88.3M | $67.6M | $69.0M | $121M | $37.0M |
| Total debt | $167M | $414M | $351M | $329M | $285M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Legend Biotech Corp. Sponsored ADR LEGN | $3.12B | -42% | +50% | 3% | 34.2× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Gilead Sciences GILD | $210B | +30% | +7% | 38% | 19.9× | -2.4% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | n/a | -35% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LEGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.5% | -0.1% | 4th lowest of 21 |
| 6-month return | -42.2% | +1.9% | lowest of 21 |
| Distance from 52-week high | -56.7% | -19.4% | lowest of 21 |
| Revenue growth (TTM) | +49.7% | +14.8% | 5th highest of 20 |
| Operating margin | 2.8% | 14.8% | 3rd lowest of 19 |
| Forward P/E | 34.2× | 20.7× | 7th most expensive of 17 |
| ROIC minus cost of capital | -2.6 pp | +7.9 pp | 4th lowest of 17 |
| EV / EBITDA | 27.6× | 30.7× | 5th cheapest of 10 |
| Net debt / EBITDA | -7.8× | -0.8× | least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |